![]() Food and Drug Administration, and the FDA’s target action date is November 29, with European approval set for next year. The Axi-cel treatment is currently under review by the U.S. The company expects axi-cel to be approved as a treatment to fight aggressive non-Hodgkin lymphoma. Kite Pharma reported a loss of 1.74 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 1.68 per share as well as the year-ago loss of 0.90 per. Kite’s biggest, most advanced offering is a CAR T therapy called axicabtagene ciloleucel, or axi-cel. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer.” Kite Pharma (KITE) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News Advertisement remove ads. “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” Gilead President and CEO John F. However, the Kite acquisition won’t become neutral in terms of earnings until the third year of the deal, according to Gilead. Gilead made it clear in its official announcement that the Kite purchase is designed to diversify its drug offerings. Shares of Kite reached a new all-time high on Monday, and the company’s shares have already traded hands more than eight times its average volume.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |